[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-427093-105":59,"doc-detail-427093-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-and-synthesis-of-new-therapeutics-for-alzheimers-disease-research-abstract","DEVELOPMENT AND SYNTHESIS OF NEW THERAPEUTICS FOR ALZHEIMER’S DISEASE - research abstract","","Alzheimer’s disease is a major cause of death among older adults, and current acetylcholinesterase (AChE)–targeted therapy is limited in halting disease progression. This study assessed 25 newly designed compounds across four libraries using an AChE inhibition assay. The workflow combined pharmacokinetic predictions, experimental solubility testing, and molecular modeling with docking to determine binding modes. Structure-activity results indicate coumarin-based analogs better fit the AChE binding site than chromene, producing low-micromolar inhibitors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-and-synthesis-of-new-therapeutics-for-alzheimers-disease-research-abstract/427093/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-and-synthesis-of-new-therapeutics-for-alzheimers-disease-research-abstract/427093.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-14","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why focus on acetylcholinesterase (AChE) in Alzheimer’s disease?","Question",{"text":112,"@type":113},"AChE breaks down acetylcholine, so inhibiting it is a therapeutic strategy for managing AD symptoms. Existing AChE inhibitors mainly address early mild-to-moderate symptoms and do not effectively stop progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the 25 new compounds evaluated in this study?",{"text":117,"@type":113},"The researchers first performed pharmacokinetic predictions, then experimentally measured solubility, followed by an AChE inhibition assay. Molecular modeling and docking were used to evaluate binding modes of the most active analogs.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the structure-activity relationship studies show?",{"text":121,"@type":113},"Coumarin was better tolerated in the AChE binding site than chromene, yielding low-micromolar inhibitors. Modifications at position 3 on the chromene moiety did not significantly affect activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},427093,1791975452,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":24},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","940 Innovation in Aging, 2025, Vol. 9, No. S2  \nAbstract citation ID: igaf122.3177  \nDEVELOPMENT AND SYNTHESIS OF NEW  \nTHERAPEUTICS FOR ALZHEIMER’S DISEASE  \nLilianna Tchatlian1, and Stevan Pecic2, 1. California State University, Fullerton, Glendale, California, United States,  \nInnovation in Aging, 2025, Vol. 9, No. S2 941  \n2. California State University, Fullerton, Fullerton, California, United States  \nAlzheimer’s disease (AD) is the sixth leading cause of death among older adults, with 1 in 3 seniors dying with AD or another form of dementia. In 2022, the U.S. had an age-adjusted mortality rate of 28.9 deaths per 100,000 people due to AD. A key therapeutic target for managing AD symptoms is acetylcholinesterase (AChE), an enzyme that breaks down acetylcholine.  \nDonepezil, the most prescribed FDA-approved drug, inhibits AChE but only addresses mild to moderate symptoms in the early stages ofAD and is inefficient in stopping the progression of the disease. The long-term goal of our lab is to develop new AChE inhibitors as potential anti-AD therapeutics. In this study we evaluated 25 new compounds, organized in 4 different libraries for their activity in AChE inhibition assay. As part of our drug design process, we first performed several pharmacokinetic predictions. Next, we experimentally determined the solubility, followed by AChE inhibition assay. Finally, using molecular modeling and docking studies, we evaluated the binding modes of the most active analogs. Our structure-activity relationship studies showed that coumarin is better tolerated in the AChE binding site than chromene, yielding low micromolar inhibitors.  \nModifications at position 3 on the chromene moiety did not significantly affect activity. Pharmacokinetic predictions suggest all new analogs can cross the blood-brain barrier, have moderate oral bioavailability and stability, and are non-toxic at therapeutic doses. The data obtained suggests that these new AChE inhibitors are good drug candidates to be further explored in preclinical studies as AD therapeutics.","cbCairoSVzU2WoD5","https://ap.wps.com/l/cbCairoSVzU2WoD5","pdf",53480,"English","# Abstract\n## Therapeutic target and rationale\n## Compound design and evaluation workflow\n## Key findings and candidate selection","[{\"question\":\"Why focus on acetylcholinesterase (AChE) in Alzheimer’s disease?\",\"answer\":\"AChE breaks down acetylcholine, so inhibiting it is a therapeutic strategy for managing AD symptoms. Existing AChE inhibitors mainly address early mild-to-moderate symptoms and do not effectively stop progression.\"},{\"question\":\"How were the 25 new compounds evaluated in this study?\",\"answer\":\"The researchers first performed pharmacokinetic predictions, then experimentally measured solubility, followed by an AChE inhibition assay. Molecular modeling and docking were used to evaluate binding modes of the most active analogs.\"},{\"question\":\"What did the structure-activity relationship studies show?\",\"answer\":\"Coumarin was better tolerated in the AChE binding site than chromene, yielding low-micromolar inhibitors. Modifications at position 3 on the chromene moiety did not significantly affect activity.\"}]","DEVELOPMENT AND SYNTHESIS OF NEW THERAPEUTICS FOR ALZHEIMER’S DISEASE - research abstract | PDF",1790642756]